Anika Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
Anika Therapeutics, Inc. (ANIK) reported Finance Lease, Right-of-Use Asset, Amortization of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2024-03-15
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-12-31 was $49.00K.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-09-30 was $50.00K.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-06-30 was $49.00K.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-03-31 was $37.00K, a 87.54% decline year-over-year.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $121.00K, a 15.38% decline from fiscal 2021.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2021 was $143.00K, a 22.70% decline from fiscal 2020.
- Anika Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2020 was $185.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 6 month as first filed | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 | ||||
| 2022-12-31 | $121.00K 10-K · filed 2024-03-15 | ||||
| 2021-12-31 | $143.00K 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $99.00K derived: sum of 2 quarters · filed 2023-03-16 | $148.00K derived: sum of 3 quarters · filed 2023-03-16 | $185.00K 10-K · filed 2023-03-16 | |
| 2020-09-30 | $50.00K 10-Q · filed 2020-11-05 | $99.00K derived: sum of 2 quarters · filed 2020-11-05 | $136.00K 10-Q · filed 2020-11-05 | $136.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-06-30 | $49.00K 10-Q · filed 2020-08-07 | $86.00K 10-Q · filed 2020-08-07 | $86.00K derived: sum of 3 quarters · filed 2022-03-11 | $86.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-03-31 | $37.00K 10-Q · filed 2020-05-22 | $37.00K derived: sum of 2 quarters · filed 2022-03-11 | $37.00K derived: sum of 3 quarters · filed 2022-03-11 | $37.00K derived: sum of 4 quarters · filed 2022-03-11 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | $591.00K 10-Q · filed 2019-07-26 | ||
| 2019-03-31 | $297.00K 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |